Shoaib Mithani
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Shoaib Mithani has a total of 14 co-authors. Here are the top co-authors by number of shared publications:
- Salman El Khalid
The Kidney Centre, Post Graduate Training Institute, Karachi-Pakistan
3 shared publications - Imran Sharif
Department of Urology, Faculty of Surgery, The Kidney Centre PGTI, Karachi-Pakistan
2 shared publications - Shariq Anis Khan
The Kidney Centre, Post Graduate Training Institute, Karachi-Pakistan
2 shared publications - Abdul Wasay Mahmood
The Kidney Centre, Post Graduate Training Institute, Karachi-Pakistan
1 shared publication - Adnan Siddiq Awan
PAF Hospital, Karachi-Pakistan
1 shared publication - Agha Zohaib
Department of Urology, Faculty of Surgery, The Kidney Centre PGTI, Karachi-Pakistan
1 shared publication
Latest Publications
- Open Access
- 1 June 2022
- Published by Advance Educational Institute and Research Center (Publications) in International Journal of Endorsing Health Science Research (IJEHSR)
- Vol. 10 (2) , 195-201
Screening of different doses of lyophilized beetroot for their hematopoietic potential.
Background: Beetroots are considered a vital source of nutrition and are usually incorporated into the daily diet to prevent different disease conditions. The therapeutic effect observed is due to the presence of active ingredients in the vegetables. The majority of our population, especially females, suffers from anemia due to malnutrition. The perseverance of this research was to explore the hematopoietic effects of lyophilized beetroot powder at different doses so they could be recommended as a nutritional supplement. Methodology: Albino rabbits weighing 1500-2000 gm of either gender were selected for the study and alienated into three sets. Set I was administered distilled water, whereas sets II and III were given lyophilized beetroot 500 mg/kg and 1000 mg/kg, correspondingly. For hematopoietic evaluation of blood, automated huma count plus was utilized. After adjusting according to their weights, lyophilized beetroot powder was suspended in distilled water and given at 500 mg/kg and 1000 mg/kg to rabbits. They were dosed once daily for two months. Results: The effects were verified before the dosing was scheduled and on the 30th day and 60th day of dosing. The outcomes presented a highly noteworthy increase (pConclusion: From the above, it can be concluded that beetroot possesses pronounced hematopoietic effects and might be beneficial as a non-pharmacological treatment for anemia and thrombocytopenia.
- 1 June 2022
- Published by Advance Educational Institute and Research Center (Publications) in International Journal of Endorsing Health Science Research (IJEHSR)
- Vol. 10 (2) , 195-201
Open AccessScreening of different doses of lyophilized beetroot for their hematopoietic potential.
Background: Beetroots are considered a vital source of nutrition and are usually incorporated into the daily diet to prevent different disease conditions. The therapeutic effect observed is due to the presence of active ingredients in the vegetables. The majority of our population, especially females, suffers from anemia due to malnutrition. The perseverance of this research was to explore the hematopoietic effects of lyophilized beetroot powder at different doses so they could be recommended as a nutritional supplement. Methodology: Albino rabbits weighing 1500-2000 gm of either gender were selected for the study and alienated into three sets. Set I was administered distilled water, whereas sets II and III were given lyophilized beetroot 500 mg/kg and 1000 mg/kg, correspondingly. For hematopoietic evaluation of blood, automated huma count plus was utilized. After adjusting according to their weights, lyophilized beetroot powder was suspended in distilled water and given at 500 mg/kg and 1000 mg/kg to rabbits. They were dosed once daily for two months. Results: The effects were verified before the dosing was scheduled and on the 30th day and 60th day of dosing. The outcomes presented a highly noteworthy increase (pConclusion: From the above, it can be concluded that beetroot possesses pronounced hematopoietic effects and might be beneficial as a non-pharmacological treatment for anemia and thrombocytopenia.
- Open Access
- 30 May 2022
- Published by Advance Educational Institute and Research Center (Publications) in International Journal of Endorsing Health Science Research (IJEHSR)
- Vol. 10 (2) , 167-171
Incidental renal neoplasia following simple nephrectomy of the non-functioning kidney. Is it more common than previously reported?
Background: Simple nephrectomy is a technique of removing the kidney from within the gerota’s fascia and is usually for a non-functioning kidney. While for renal tumors, radical nephrectomy is done, which involves the removal of the kidney with gerota’s fascia along with the ureter. Histopathology of patients who undergo simple nephrectomy sometime reveals renal malignancy. Such patients often need further treatment as simple nephrectomy in such cases is mostly suboptimal. The number of studies reporting tumors in simple nephrectomy specimens is limited. We aim to report single-center pathological findings in nephrectomy specimens from patients treated for non-functioning kidneys due to renal stone disease. Methodology: The medical record of patients (n=210) who underwent simple nephrectomy between 2014 and 2021 at the Kidney Centre Postgraduate Training Institute due to renal stone disease was reviewed retrospectively. Results: The total number of patients undergoing simple nephrectomy for non-functioning kidneys due to stone disease was 210. Of those patients, 117 were males, and 93 were females. The mean age was 45.33 ± 17.65 years. The histopathology report of specimens revealed renal malignancy in 10 patients (4.76%), xanthogranulomatous pyelonephritis in 11 patients, tuberculosis of the kidney in 7 patients, and chronic pyelonephritis in 182 patients. Conclusion: In conclusion, the prevalence of renal malignancy in patients undergoing simple nephrectomy is significantly high.
- 30 May 2022
- Published by Advance Educational Institute and Research Center (Publications) in International Journal of Endorsing Health Science Research (IJEHSR)
- Vol. 10 (2) , 167-171
Open AccessIncidental renal neoplasia following simple nephrectomy of the non-functioning kidney. Is it more common than previously reported?
Background: Simple nephrectomy is a technique of removing the kidney from within the gerota’s fascia and is usually for a non-functioning kidney. While for renal tumors, radical nephrectomy is done, which involves the removal of the kidney with gerota’s fascia along with the ureter. Histopathology of patients who undergo simple nephrectomy sometime reveals renal malignancy. Such patients often need further treatment as simple nephrectomy in such cases is mostly suboptimal. The number of studies reporting tumors in simple nephrectomy specimens is limited. We aim to report single-center pathological findings in nephrectomy specimens from patients treated for non-functioning kidneys due to renal stone disease. Methodology: The medical record of patients (n=210) who underwent simple nephrectomy between 2014 and 2021 at the Kidney Centre Postgraduate Training Institute due to renal stone disease was reviewed retrospectively. Results: The total number of patients undergoing simple nephrectomy for non-functioning kidneys due to stone disease was 210. Of those patients, 117 were males, and 93 were females. The mean age was 45.33 ± 17.65 years. The histopathology report of specimens revealed renal malignancy in 10 patients (4.76%), xanthogranulomatous pyelonephritis in 11 patients, tuberculosis of the kidney in 7 patients, and chronic pyelonephritis in 182 patients. Conclusion: In conclusion, the prevalence of renal malignancy in patients undergoing simple nephrectomy is significantly high.
- Open Access
- 14 April 2021
- Published by Advance Educational Institute and Research Center (Publications) in International Journal of Endorsing Health Science Research (IJEHSR)
- Vol. 9 (2) , 156-160
Transurethral Resection of Prostate and Blood loss: Efficacy of Dutasteride in reducing perioperative blood loss.
Background: Benign Prostatic Hyperplasia (BPH) is the most common urological cause of urinary obstruction, affecting men above 50 years of age. Medical therapy used for managing BPH includes various medical regimes, including 5-alpha reductase inhibitors (5ARI), namely Dutasteride and more. The study aimed to evaluate the efficacy of four weeks' prior treatment with dutasteride on per-operative blood loss in patients of BPH undergoing transurethral resection of the prostate. Methodology: A prospective observational study was conducted from January to December 2019 at the Kidney Centre, Karachi, Pakistan. A total of 64 patients were included and divided into two groups. Group A patients were those who had been taking dutasteride (0.5 mg/day) for four weeks or more before surgery, and group B patients were not taking dutasteride drug before surgery. All patients underwent standard TURP, and the intra-operative blood loss was calculated. The collected data was analyzed using SPSS version 22.0. Results: In our study, there was a significantly less hemoglobin drop (1.2 gm vs. 2.2 gm) during prostate surgery in patients using dutasteride than those who were not using dutasteride. Conclusion: This study has revealed that the use of dutasteride four weeks before surgery significantly reduces intra-operative bleeding.
- 14 April 2021
- Published by Advance Educational Institute and Research Center (Publications) in International Journal of Endorsing Health Science Research (IJEHSR)
- Vol. 9 (2) , 156-160
Open AccessTransurethral Resection of Prostate and Blood loss: Efficacy of Dutasteride in reducing perioperative blood loss.
Background: Benign Prostatic Hyperplasia (BPH) is the most common urological cause of urinary obstruction, affecting men above 50 years of age. Medical therapy used for managing BPH includes various medical regimes, including 5-alpha reductase inhibitors (5ARI), namely Dutasteride and more. The study aimed to evaluate the efficacy of four weeks' prior treatment with dutasteride on per-operative blood loss in patients of BPH undergoing transurethral resection of the prostate. Methodology: A prospective observational study was conducted from January to December 2019 at the Kidney Centre, Karachi, Pakistan. A total of 64 patients were included and divided into two groups. Group A patients were those who had been taking dutasteride (0.5 mg/day) for four weeks or more before surgery, and group B patients were not taking dutasteride drug before surgery. All patients underwent standard TURP, and the intra-operative blood loss was calculated. The collected data was analyzed using SPSS version 22.0. Results: In our study, there was a significantly less hemoglobin drop (1.2 gm vs. 2.2 gm) during prostate surgery in patients using dutasteride than those who were not using dutasteride. Conclusion: This study has revealed that the use of dutasteride four weeks before surgery significantly reduces intra-operative bleeding.